Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 1,112.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 313,407 shares of the biopharmaceutical company’s stock after buying an additional 287,549 shares during the period. Squarepoint Ops LLC’s holdings in Sage Therapeutics were worth $3,404,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Cubist Systematic Strategies LLC boosted its holdings in shares of Sage Therapeutics by 831.2% during the second quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock valued at $5,312,000 after acquiring an additional 436,566 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Sage Therapeutics during the second quarter worth approximately $153,000. Marshall Wace LLP bought a new position in Sage Therapeutics in the 2nd quarter worth approximately $1,178,000. Inspire Investing LLC increased its position in Sage Therapeutics by 69.7% in the 2nd quarter. Inspire Investing LLC now owns 32,633 shares of the biopharmaceutical company’s stock valued at $354,000 after acquiring an additional 13,399 shares during the period. Finally, XTX Topco Ltd bought a new stake in Sage Therapeutics during the 2nd quarter valued at $524,000. Institutional investors own 99.22% of the company’s stock.

Wall Street Analyst Weigh In

SAGE has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered their price target on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating on the stock in a report on Friday, July 26th. Robert W. Baird dropped their price target on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Scotiabank decreased their price objective on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a report on Thursday, July 25th. HC Wainwright reissued a “neutral” rating and set a $25.00 target price on shares of Sage Therapeutics in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. decreased their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and an average price target of $16.06.

Sage Therapeutics Trading Down 3.6 %

Shares of SAGE opened at $6.96 on Wednesday. The company has a 50-day moving average of $8.42 and a two-hundred day moving average of $11.59. Sage Therapeutics, Inc. has a one year low of $6.89 and a one year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The firm had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. During the same period in the prior year, the business posted ($2.68) EPS. The company’s revenue for the quarter was up 249.8% on a year-over-year basis. Equities analysts forecast that Sage Therapeutics, Inc. will post -6.47 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.